Home / Blog / Aberrant splicing prediction across human tissues

Aberrant splicing prediction across human tissues

Jun 09, 2023Jun 09, 2023

Nature Genetics volume 55, pages 861–870 (2023)Cite this article

14k Accesses

2 Citations

171 Altmetric

Metrics details

Aberrant splicing is a major cause of genetic disorders but its direct detection in transcriptomes is limited to clinically accessible tissues such as skin or body fluids. While DNA-based machine learning models can prioritize rare variants for affecting splicing, their performance in predicting tissue-specific aberrant splicing remains unassessed. Here we generated an aberrant splicing benchmark dataset, spanning over 8.8 million rare variants in 49 human tissues from the Genotype-Tissue Expression (GTEx) dataset. At 20% recall, state-of-the-art DNA-based models achieve maximum 12% precision. By mapping and quantifying tissue-specific splice site usage transcriptome-wide and modeling isoform competition, we increased precision by threefold at the same recall. Integrating RNA-sequencing data of clinically accessible tissues into our model, AbSplice, brought precision to 60%. These results, replicated in two independent cohorts, substantially contribute to noncoding loss-of-function variant identification and to genetic diagnostics design and analytics.

Identifying noncoding loss-of-function DNA variants is a major bottleneck of whole genome interpretation, as predicting function outside coding regions is difficult1. Variants altering splicing represent an important class of noncoding loss-of-function variants because they can lead to drastically altered RNA isoforms, for instance, by inducing frameshifts or ablations of functionally important protein domains. If the variant strongly alters splicing isoform choice, the remaining abundance of functional RNA isoforms can be so reduced that the function of the gene is lost. Due to the relevance of splicing for variant interpretation, notably in rare disease diagnostics and in oncology, algorithms have been developed to predict whether variants affect splicing2,3,4,5,6,7,8,9. However, only recently, aberrant splicing events, that is, rare large alterations of splice isoform usage, have been called in human tissues10,11,12. While a method to a posteriori prioritize candidate causal rare variants for observed aberrant splicing events has been proposed12, the forward problem, that is, predicting among rare variants which ones will result in aberrant splicing, has not been addressed.

Here, we set out to establish models predicting whether a rare variant associates with aberrant splicing in any given human tissue. First, we assumed only DNA to be available and later on further considered complementary RNA-sequencing (RNA-seq) data of clinically accessible tissues (CATs) (Fig. 1).

We set out to predict whether rare variants associate with aberrant splicing across 49 human tissues. a, We established a comprehensive benchmark for aberrant splicing by processing GTEx samples with a recently published aberrant splicing caller10 based on which we could assess and develop predictors that could take as input DNA sequence and, optionally, RNA-seq data of CATs. b, Benchmarking revealed modest performance of currently used algorithms based on DNA only, a substantial performance improvement when integrating these models with SpliceMap, a quantitative map of tissue-specific splicing we developed in this study, and further improvements when also including direct measures of aberrant splicing in accessible tissues.

We created a benchmark using the aberrant splicing caller FRASER (Find RAre Splicing Events in RNA-seq)10 on 16,213 RNA-seq samples of the Genotype-Tissue Expression (GTEx) dataset, spanning 49 tissues and 946 individuals. Compared with other splicing outlier detection methods11,12, FRASER consistently showed the highest agreement with sequence-based predictors and was therefore subsequently used for our evaluations (Extended Data Fig. 1). For every individual, we considered every protein coding gene carrying at least one rare variant (minor allele frequency (MAF) less than 0.1% based on the Genome Aggregation Database (gnomAD)13 and found in no more than two individuals across GTEx) and set out to predict in which tissue, if any, is this gene aberrantly spliced. We defined a gene to be aberrantly spliced in a sample if it was called as a transcriptome-wide significant splicing outlier and with a sufficient amplitude (differential percent spliced-in (Ψ) larger than 0.3; Methods, and see Extended Data Fig. 1 for results with alternative cutoffs). Previous studies had reported that as many as 75% of aberrant splicing events in GTEx RNA-seq samples are not replicated across tissues10,12 and thus may reflect technical artifacts or aberrant splicing that is not genetically driven. We quantified the enrichment of replicated splicing outliers across tissues of the same individual with respect to the distance to the closest rare variant and found them to be enriched up to a distance of 250 base pairs (bp) (Extended Data Fig. 2). Therefore, we also required a rare variant to be less than 250 bp away from the boundaries of any intron associated with the aberrantly spliced splice site (Methods and Extended Data Fig. 3). This filter yielded similar results as filtering for replicated aberrant events with the extra advantage of being applicable to independent cohorts that have a single sample per individual (Extended Data Fig. 4).

We then assessed the performance of two complementary state-of-the-art sequence-based deep learning models: modular modeling of splicing (MMSplice)3, which predicts quantitative usage changes of predefined splice sites within a 100-bp window of a variant, and SpliceAI2, which is independent of gene annotations and predicts creation or loss of splice sites within a 50-bp window of a variant (Extended Data Fig. 5). Using larger prediction window sizes for SpliceAI did not improve the results (Supplementary Fig. 1). For individuals with multiple rare variants on a gene, we retained the highest score of each model. Out-of-the-box application of MMSplice and SpliceAI showed a modest performance, with an overall precision of 8% for MMSplice and of 12% for SpliceAI at 20% recall, and an area under the precision–recall curve (auPRC) of 4% ± 1 percentage point across tissues for MMSplice and 5% ± 2 percentage points for SpliceAI.

We observed that many false predictions originated from inaccurate genome annotations. On the one hand, standard genome annotations are not tissue-specific, leading to false positive predictions. This includes predictions for genes that are not expressed in the tissue of interest, as for the gene TRPC6 in the brain (Fig. 2a), and, among expressed genes, predictions for exons that are not canonically used in the tissue, as for exon 2 of C2orf74 in the tibial nerve (Fig. 2b). On the other hand, many splice sites are missing from standard genome annotations14,15. These nonannotated splice sites are often spliced at a low level, yet can be strongly enhanced by variants (see Fig. 2c for an example) and are suspected to be a major cause of aberrant splicing16,17. To address all these issues, we created a tissue-specific splice site map, which we named SpliceMap, using GTEx RNA-seq data. SpliceMap excludes untranscribed splice sites and introns for each tissue and includes nonannotated splice sites and introns reproducibly observed among samples of the same tissue (Methods). The standard genome annotation GENCODE18 (release 38 of hg38) contains 244,189 donor sites and 235,654 acceptor sites, of which 93% were detected at least in one GTEx tissue (Fig. 2d). SpliceMap contains 168,004 ± 9,288 donor sites and 164,702 ± 8,950 acceptor sites per tissue (Extended Data Fig. 6). From this total, 7,060 ± 3,706 donor sites and 8,222 ± 3,740 acceptor sites were unannotated, with testis containing the maximum number of nonannotated donor and acceptor sites (29,673 and 29,911 respectively), in line with the unique transcriptional and splicing patterns of testis19,20. SpliceMap is robust to variations in sample size and to different split-read counting tools21,22 (Supplementary Fig. 2). Moreover, we found that currently available long-read RNA-seq data in GTEx23 were not yet sensitive enough24 to reliably identify nonannotated splice sites (Supplementary Fig. 2). Applying MMSplice on the tissue-specific splice sites defined by SpliceMap increased the precision of MMSplice to 13% at 20% recall (Fig. 2e), with a significantly higher auPRC consistently across tissues (Fig. 2f). Similarly, applying SpliceMap on SpliceAI increased precision to 22% at 20% recall.

a–c, Sashimi plots showing RNA-seq read coverage (y axis) and the numbers of split reads spanning an intron indicated on the exon-connecting line (using pysashimi50) for instances illustrating the benefits of the SpliceMap annotation. For each instance, two individuals are displayed. The individual with the rare genetic variant (located at the dashed black line) is shown in the lower track (darker color). SpliceMap catalogs expressed genes and splice sites in each tissue and can thus help in identifying cases for which there is no variant effect in tissues not expressing the whole gene (a) or the exon (b) in proximity of the variant. Moreover, SpliceMap includes weak splice sites, which are spliced at a low level, but can be activated and create novel exons in the presence of a variant (c). d, Venn diagram comparing annotated splice sites in standard genome annotation (GENCODE release 38) and SpliceMap aggregating all GTEx tissues. e, Precision–recall curves comparing the overall prediction performance across all GTEx tissues (n = 49) of MMSplice applied to GENCODE splice sites, MMSplice applied to tissue-specific splice sites according to SpliceMap, SpliceAI and SpliceAI using tissue-specific SpliceMaps. f, Distribution of the auPRC across all GTEx tissues of the models in e. Center line, median; box limits, first and third quartiles; whiskers span all data within 1.5 interquartile ranges of the lower and upper quartiles. P values were computed using the paired one-sided Wilcoxon test. Alt, alternative; Ind, individual; Ref, reference.

Variants affecting splicing typically associate with abundance ratio fold-changes of competing splicing isoforms, which result in nonlinear effects on isoform proportions according to the so-called scaling law of splicing25,26. For instance, starting from a 1:1 ratio between one splicing isoform and its alternative in a major allele background, a tenfold decrease leads to a 1:10 ratio, which amounts to around 40 percentage points decrease (from 50% to approximately 10%). However, the same ratio fold-change starting from a 1:10 ratio amounts to less than 1 percentage point decrease (Extended Data Fig. 7). Hence, the scaling law of splicing implies that the variation of isoform abundance between tissues in major allele background alone can explain some of the tissue-specific effects of variants on isoform proportion25, as exemplified with exon 7 of the gene TRPC6 (Fig. 3a). We estimated major allele background levels of alternative donor and acceptor splice site usage proportions for all introns and all tissues of SpliceMap (Extended Data Fig. 7). Integrating these reference levels further improved the MMSplice predictions by 1.6-fold consistently across tissues, and to a lesser extent the SpliceAI predictions (Fig. 3b,c and Methods). We suspect that MMSplice showed stronger relative improvement compared with SpliceAI because it models percent spliced-in of predefined splice sites and can integrate in a principled fashion reference levels using the scaling law. In contrast, SpliceAI models creation or loss of splice sites. We integrated reference levels with SpliceAI by applying filters (Methods). However, predicted activations of annotated splice sites and predicted deactivations of unannotated splice sites are already masked in SpliceAI, thereby qualitatively capturing the effect of using reference level filters for a large number of splice sites.

a, Sashimi plot of TRPC6 around exon 7 in lung and brain for two individuals, one carrying no rare variant in this region (control, upper tracks), and one carrying an exonic rare deletion (dashed line and lower tracks) associated with reduced splicing of exon 7. The donor sites of exon 6 and exon 7 compete against each other for splicing with the acceptor site of exon 8. For the control individual, the donor site of exon 7 is used 70% of the time in the lung, and only 11% of the time in the brain. The variant associates with a stronger difference (33 percentage points) in the lung than in the brain (1 percentage point). b, Precision–recall curve comparing the overall prediction performance on all GTEx tissues of SpliceAI, SpliceAI using SpliceMap, SpliceAI using SpliceMap along with quantitative reference levels of splicing, MMSplice using GENCODE annotation, MMSplice using SpliceMap annotation, MMSplice using SpliceMap annotation along with quantitative reference levels of splicing and the integrative model AbSplice-DNA. Different cutoffs are shown (SpliceAI, high: 0.8, medium: 0.5, low: 0.2; MMSplice (score absolute value), high: 2, medium: 1.5, low: 1; AbSplice-DNA, high: 0.2, medium: 0.05, low: 0.01). c, Distribution of the auPRC of the models in b across tissues (n = 49). Center line, median; box limits, first and third quartiles; whiskers span all data within 1.5 interquartile ranges of the lower and upper quartiles. P values were computed using the paired one-sided Wilcoxon test. d, Model performance across different VEP51 variant categories. Categories are ordered from left to right by decreasing severity. Each annotated variant is labeled by its most severe category. The ‘Exon’ category consists of the VEP categories stop gained, stop lost, missense and synonymous. e, Model performance across nonexclusive outlier outcome categories (Methods). For panels d and e, the ‘All’ category contains all unique variants (independent of the VEP annotation and outlier outcome categories) and n is the number of variants associated with outliers.

Next, to leverage the complementarity of MMSplice and SpliceAI predictions7, we trained a generalized additive model using the scores from both deep learning models as well as annotation features from tissue-specific SpliceMaps (Methods). This model, which we call AbSplice-DNA, achieved an additional 1.5-fold improvement (Fig. 3b,c). The AbSplice-DNA scores are probability estimates which we found to be well calibrated on GTEx (Extended Data Fig. 8). AbSplice predicts for each variant how likely aberrant splicing of some sort takes place in a given tissue and reports the splice site with the strongest effect (see Supplementary Table 1 for an example). To ease downstream applications we suggest three cutoffs (high: 0.2, medium: 0.05, low: 0.01), which have approximately the same recalls as the high, medium and low cutoffs of SpliceAI (Fig. 3b).

We also tested integration of other predictors into AbSplice-DNA by including scores from Combined Annotation Dependent Depletion-Splice (CADD-Splice)7, Multi-tissue Splicing (MTSplice)9 and Super Quick Information-content Random-forest Learning of Splice variants (SQUIRLS)8 (Methods). However, those models only led to minor improvements (Extended Data Fig. 9). We decided to incorporate only MMSplice and SpliceAI into the final model so as not to have a model confounded by conservation information (used by CADD-Splice and SQUIRLS), and to keep the possibility to easily integrate new tissues which would not be the case with MTSplice. Nevertheless, the code of AbSplice can easily be modified to incorporate new features. We also tried random forest and logistic regression as alternative machine learning models, which gave similar performances to the generalized additive model (Methods and Extended Data Fig. 9).

We evaluated the model performances in more detail by stratifying the results on two different scenarios. First, we stratified by variant categories. As expected, the precision was the best on variants affecting the donor and acceptor dinucleotides on all models, followed by variants in the splice region (within 1–3 bases of the exon or 3–8 bases of the intron), then in the exonic, and lastly in the intronic regions (Methods and Fig. 3d). AbSplice-DNA outperformed all models throughout all variant categories, including intronic variants, whose effects are notoriously more difficult to predict. Second, we analyzed the model performance for five nonexclusive aberrant splicing outcomes: exon elongation, exon truncation, exon skipping, any alternative donor or acceptor choice outlier, and any splicing efficiency outlier. AbSplice-DNA performed better for exon skipping than for exon elongation and truncation, as well as better for alternative donor or acceptor choice than for splicing efficiency outliers. Moreover, AbSplice-DNA outperformed all other models throughout all investigated outlier outcome categories (Fig. 3e).

Having established our model on GTEx, we next assessed how well the performance replicated in independent cohorts. We first evaluated a dataset consisting of RNA-seq samples from skin fibroblasts of 303 individuals with a suspected rare mitochondriopathy27. We found that there was a large overlap (86%) of splice sites in SpliceMaps generated from GTEx fibroblasts and from this cohort (Fig. 4a and Supplementary Fig. 3). Moreover, we observed consistent reference levels of splicing between the two datasets (Fig. 4b, Pearson correlation 0.87). We applied AbSplice-DNA trained on GTEx using the SpliceMap from GTEx fibroblasts on the subset of this data for which whole genome sequencing (WGS) was available (n = 20) and used aberrant splicing calls performed on the RNA-seq samples to assess the predictions. The relative improvements between the baseline models and AbSplice-DNA replicated. AbSplice-DNA achieved 13.2 ± 1.5% auPRC, 2.5-fold higher than SpliceAI or MMSplice alone (Fig. 4c). From a rare variant prioritization standpoint, AbSplice-DNA typically gave about twofold fewer candidate predictions at the same level of recall than SpliceAI, itself comparing favorably over MMSplice (Supplementary Fig. 4). Hence, AbSplice-DNA can help rare disease diagnostics by providing substantially shorter lists of predicted candidate variants to investigate compared with state-of-the–art sequence-based models.

a, Venn diagram comparing the splice sites in the SpliceMap generated from fibroblasts from a mitochondrial disease dataset (n = 303) and GTEx (n = 492). b, Correlation of the reference Ψ values from the union of introns of the SpliceMaps from a. For the union of introns: n = 736,503, Pearson correlation = 0.87, R2 = 0.74, where reference Ψ of nonintersecting introns was set to zero. For the intersection of introns: n = 522,876, Pearson correlation = 1.0, R2 = 0.99. c, AuPRC for classification of aberrant splicing events from rare variants in the mitochondrial disease dataset for SpliceAI, MMSplice and AbSplice-DNA trained on GTEx using the GTEx fibroblasts SpliceMap from a. Error bars represent s.e.m. (Jackknife over samples, n = 20). d, Enrichment of high-score predictions in ALS genes (n = 165). Cutoffs are for SpliceAI (high: 0.8), MMSplice (high: 2) and AbSplice-DNA (high: 0.2). The sample size n in the x-axis labels corresponds to the total number of predictions above the cutoff. P values were computed using one-sided Fisher tests considering all protein coding genes as the universe. e, Proportion of rare variants that pass the high cutoffs described in d for MMSplice with GENCODE annotation, SpliceAI and AbSplice-DNA trained on GTEx and using GTEx brain SpliceMaps as well as a SpliceMap from ALS motor neurons, validated using proteomics (Z-score < −2; Methods) in the ALS dataset. The sample size n in the y-axis labels corresponds to the total number of predictions above the cutoff. Error bars represent 95% CIs from the binomial test. f, Genome-wide depletion of high-impact variants among rare SNVs (gnomAD MAF < 0.1%) within a gene (n = 19,534) as a function of LOEUF score deciles. High-impact variants are defined by a SpliceAI score > 0.8, MMSplice score > 2 (absolute score) and an AbSplice-DNA score > 0.2 in at least one tissue. Asterisks mark significance levels of two-sided Fisher tests of AbSplice-DNA compared with SpliceAI (*<0.05, **<10−4, ***<10−8). NS, not significant.

We next considered a cohort of WGS samples paired with RNA-seq and proteomics data of induced pluripotent stem cell (iPSC)-derived spinal motor neurons from 245 amyotrophic lateral sclerosis (ALS)-affected and 45 healthy individuals from the Answer ALS project (Methods). As iPSC-derived spinal motor neurons were not profiled in GTEx, we considered two approaches. On the one hand, we used the Answer ALS healthy controls to generate a SpliceMap for iPSC-derived spinal motor neurons. On the other hand, we used the SpliceMap of GTEx brain tissues as a proxy which showed the highest overlap from all GTEx tissues (Supplementary Fig. 5). We found that the GTEx SpliceMap from brain tissues agreed reasonably well with the one derived from this cohort both qualitatively (76% shared splice sites) and quantitatively (Pearson correlation 0.86; Supplementary Fig. 5). Here, too, AbSplice-DNA outperformed SpliceAI and MMSplice. Interestingly, AbSplice-DNA achieved similar performances using the SpliceMap from GTEx brain tissues or using the SpliceMap from iPSC-derived spinal motor neurons, suggesting that AbSplice-DNA can be applied robustly in absence of control samples using SpliceMaps from proxy tissues (Supplementary Fig. 6). Moreover, AbSplice-DNA predictions were enriched for genes associated with ALS28,29,30,31,32 (threefold enrichment; Fig. 4d), which was less so for MMSplice predictions and not the case for SpliceAI predictions. We further validated AbSplice-DNA using proteomics data available for this cohort. At our recommended cutoff, AbSplice-DNA predicted 58 genes to be aberrantly spliced, of which 31% (18 of 58; 95% confidence interval (95% CI), 20–45%) of the corresponding proteins showed significantly low abundance (Z-score < −2; Methods), consistent with RNA degradation via nonsense-mediated decay or protein isoforms resulting from aberrant splicing events that are more poorly translated or less stable. Similarly, independent confirmation by proteomics led to validation rates of MMSplice (26 of 183; 95% CI, 9–20%) and SpliceAI (17 of 80; 95% CI, 13–32%) consistent with the validation rates we originally observed at those cutoffs using the GTEx RNA-seq benchmark (Fig. 3b). Altogether, the proteomics analyses confirm the relative improvements of the different models and are overall consistent with our precision estimates.

Furthermore, we applied AbSplice-DNA to 203,306,868 rare variants (MAF < 0.1%) from the gnomAD dataset using SpliceMaps from all GTEx tissues. In highly constrained genes, defined as the 10% of genes most strongly depleted for loss-of-function variants in gnomAD13, rare variants were more strongly depleted for high AbSplice-DNA scores in at least one tissue (3.4-fold depletion), than for high SpliceAI scores (2.9-fold depletion, P < 10−21; Fig. 4f) or high MMSplice scores (2.2-fold depletion). A stronger depletion than with SpliceAI or MMSplice also held when relaxing the AbSplice-DNA cutoff to match the total number of predictions of SpliceAI (Supplementary Fig. 7).

Collectively, these results on independent data demonstrate the robustness and the applicability of AbSplice-DNA and suggest its utility for rare disease diagnostics and rare variant interpretation.

Sequencing transcriptomes of CATs such as skin or body fluids is of increasing interest in rare disease research as it allows direct detection of aberrant splicing for those splice sites used both in the CAT and in tissues of suspected disease relevance16,33,34,35. The GTEx dataset consists of post-mortem-collected RNA-seq samples across a vast variety of tissues and thereby offers the unique opportunity to evaluate to what extent aberrant splicing in an accessible tissue reflects aberrant splicing of another tissue of interest. One positive example in GTEx is aberrant splicing of DDX27 in the heart which can also be observed in skin fibroblasts (Fig. 5a). Consistent with a previous study35 based on the Ensembl gene annotation36, we found that among the CATs, fibroblasts have the highest overlap of transcribed splice sites according to SpliceMap with nonaccessible tissues, followed by lymphocytes and whole blood (Fig. 5b). To predict aberrant splicing in nonaccessible tissues, we considered ranking genes of an individual first for showing significant and large aberrant splicing in a CAT (false discovery rate (FDR) < 0.1 and |ΔΨ| > 0.3) and then by significance level. This simple method yielded a markedly increased precision compared with the DNA-based models, up to nearly 40% recall (Fig. 5c and Extended Data Fig. 10a). However, RNA-based predictions remain limited to those splice sites expressed and spliced in the CAT. Therefore, we next trained models integrating AbSplice-DNA features together with RNA-seq-based features from CATs, including differential splicing amplitude estimates to leverage the splicing scaling law and the SpliceMaps (Methods). These models, which we call AbSplice-RNA, outperformed all other models (Fig. 5c and Extended Data Fig. 10a). We found that using fibroblasts only led to the same performance as using all CATs, reaching around 60% precision at 20% recall and amounting to a twofold improvement over AbSplice-DNA (Fig. 5c and Extended Data Fig. 10b). Those improvements were consistent across target tissues (Fig. 5d). As expected, AbSplice-RNA outperformed AbSplice-DNA for genes expressed in CATs and remained on par with it otherwise (Extended Data Fig. 10c). Altogether, these results establish a formal way to integrate direct measurements of aberrant splicing along with sequence-based models to predict aberrant splicing in a tissue of interest.

a, Sashimi plot of DDX27 around exon 10 for two individuals in heart and fibroblasts. One individual carries no rare variant in this region (control, upper tracks), and one carries an exonic rare variant (dashed line, lower tracks) associated with increased splicing of exon 10. This exon shows a similar usage in fibroblasts and in the heart (reference donor site percent spliced-in, Ψ3 = 8%, according to SpliceMap in both tissues, in line with the measured values for the displayed control individual: Ψ3 = 6% in heart and Ψ3 = 5% in fibroblasts). The effect associated with the variant in fibroblasts approximates well the one in heart (difference of donor site usage, ΔΨ3 = 50% in heart and 37% in fibroblasts). In this case, aberrant splicing can be directly detected from the accessible tissue. b, Proportion of splice sites used in GTEx clinically nonaccessible target tissues (rows) also used in GTEx CATs (columns). c, Precision–recall curve comparing the overall prediction performance on all GTEx tissues of SpliceAI, MMSplice using GENCODE annotation, AbSplice-DNA, gene-level FRASER P values in fibroblasts and AbSplice-RNA, which integrates AbSplice-DNA features with features from RNA-seq from fibroblasts. d, Distribution of the auPRC of the models in c across tissues (n = 49). Center line, median; box limits, first and third quartiles; whiskers span all data within 1.5 interquartile ranges of the lower and upper quartiles; P values were computed using the paired one-sided Wilcoxon test.

We established a comprehensive benchmark for predicting variants leading to aberrant splicing in human tissues, revealing limited performance of state-of-the-art sequence-based models. We created a tissue-specific splicing annotation (SpliceMap) based on GTEx which maps acceptor and donor splice sites and quantifies their usage in 49 human tissues. We showed that integrating SpliceMap with DNA-based prediction models leads to a threefold increase of precision at the same recall. Additionally, we found that RNA-seq from CATs complements DNA-based splicing predictions when incorporated into an integrative model.

The prediction of splicing-perturbing variants has a long history of over 20 years’ work2,3,4,5,6,7,8,9,26,37,38,39,40,41,42,43,44. This includes tissue-specific models for mouse43,44 and more recently human9,41. Those models showed successes in various splicing prediction tasks, such as quantitative change of percent spliced-in, splice site usage or splicing efficiency. This study mainly focuses on the prediction of extreme splicing effects (outliers), which has not yet been assessed. This modeling task could be investigated only now, after the development of aberrant splicing callers10,11,12 which enabled the establishment of a ground truth for splicing outlier prediction. We foresee that the paradigm of predicting extreme effects in splicing from DNA could be an inspiration for future research and further be extended to aberrant expression or protein abundance prediction. Furthermore, the large multi-tissue cohorts provided by GTEx allowed us to assess and develop tissue-specific predictors. Using aberrant splicing predictions for tissues that are mechanistically related to the disease of interest may prove to be helpful to identify the effector gene, just as tissue-specific predictions are important for transcriptome-wide association studies45.

Some splicing variant effect prediction models leverage conservation as further evidence of the functional relevance of a variant7,8. Even though conservation is a strong indicator of function, we decided not to include conservation in our final model, as variants causing aberrant splicing do not necessarily have to reside on conserved regions. Moreover, conservation depends on the functional importance of the gene. A nucleotide strongly affecting splicing of a nonconserved gene may be less conserved than a nucleotide with a milder effect on splicing located in a highly conserved gene. Also, a nucleotide can be conserved due to its other potential roles besides splicing. For example, exonic regions near splice sites might be conserved due to their role in protein function. Altogether, even though conservation could still marginally yet significantly improve our model (Extended Data Fig. 9), we opted to provide to the community a model predicting aberrant splicing per se by integrating models solely trained on DNA sequence and splicing metrics measured from RNA-seq or massively parallel reporter assays (MPRAs) (SpliceAI and MMSplice). AbSplice users can still benefit from conservation evidence in post-processing steps to further prioritize variants.

We constructed SpliceMaps and detected aberrant splicing from short-read RNA-seq. We found that current long-read RNA-seq data available for GTEx23 did not provide sufficient coverage to detect unannotated splice sites (Supplementary Fig. 2). Since split short reads reveal splice sites, we foresee that the major added value of long-read over short-read sequencing is not about calling splice sites but identifying the complete RNA isoforms. This could be used in the future to develop models predicting the exact splicing outcome (for example, exact elongated or truncated exon boundaries, exon combinations and so on) caused by the variant, which is beyond the scope of current models trained primarily on short-read data.

We showed how RNA-seq of CATs effectively complements DNA-based predictions. An alternative to this approach is to reprogram or transdifferentiate cells into the suspected mechanistically involved cell type and perform RNA-seq on them46. This approach has, however, important caveats. First, it is not ensured that the suspected mechanistically involved cell type is the correct one, as symptoms may manifest more strongly in downstream affected tissues. Second, this approach is cost, time and labor intensive. Third, cell reprogramming can induce and select mutations which may lead to false identifications. Therefore, predictive models that can leverage RNA-seq of CATs will probably remain relevant in practice47. Furthermore, RNA-seq reveals the consequence of the splicing defect on the resulting transcript isoform (for example, frameshift or exon truncation), which is crucial for diagnostics.

By increasing the precision at 20% recall from about 10% to 60%, the cumulative improvements of our models are substantial. Still, a majority of the aberrant splicing events are not recalled and there remains a majority of false positives. An unknown and potentially large fraction of events that are not recalled might be aberrant splicing calling artifacts, as suggested by the high number of singleton calls. In this study, we implemented strategies aiming at improving the proportion of genuine genetically driven aberrant splicing events in the ground truth while not introducing biases favoring particular models (Extended Data Figs. 2–4). However, every classification task is founded on a reliable ground truth. As splicing is a complex process and not all aberrant events can be reliably called by state-of-the art aberrant splicing callers, the ground truth in the prediction task remains a proxy. Progress in aberrant splicing calling or better understanding of the technical reasons could reduce the number of incorrectly called aberrant splicing events and improve the recall. Moreover, some of the apparent false positive predictions may be actually correct. This is the case when the aberrant splicing isoform contains a premature termination codon and, often, though not systematically48, gets rapidly degraded by nonsense-mediated decay. Rapidly degraded isoforms barely have any reads in RNA-seq data and hence are typically not detected by aberrant splicing callers. In diagnostic applications, those variants remain relevant. Moreover, dedicated experiments can be done to test whether aberrant splicing is taking place, for instance, using the translation inhibitor cycloheximide.

As WGS becomes more readily available in research and healthcare, there is a growing need for accurate annotation of noncoding variants with strong deleterious effects for establishing genetic diagnostics of rare disorders, identifying effector genes of common diseases and more precisely stratifying patients with cancer based on their tumor genetic alterations. Variants causing aberrant splicing are not only a major class of such noncoding loss-of-function variants, but their mechanisms of action also now become targetable for an increasingly rich therapeutic arsenal49. Hence, because of its high precision and its focus on extreme events, we foresee AbSplice to be instrumental for genome-based diagnostics and therapy design.

No primary data were generated for this study. Person-related data were obtained through authorized access from primary data controllers. The study adheres to the ethical and research agreements between the Technical University of Munich and the primary data controllers. All participant informed consents were collected by and remain with the primary data controllers.

No statistical method was used to predetermine sample size. We did not use any study design that required randomization or blinding. In the GTEx data we excluded tissues with fewer than 50 samples. In the ALS and mitochondrial disease datasets we did not exclude any samples.

We downloaded the RNA-seq read alignment files (BAM files) and the variant calling files (VCF files) from WGS from GTEx v8p (hg38) from the database of Genotypes and Phenotypes (dbGaP) (study accession: phs000424.v8.p2). We used data from 946 individuals with paired WGS and RNA-seq measurements (n = 16,213) in at least one tissue. For the long-read RNA-seq data, we downloaded the transcript annotation (GTF) generated by FLAIR52 based on 88 Nanopore samples from the GTEx portal.

The dataset consists of 303 patients with mitochondriopathy described by Yépez et al.27, all of which have RNA-seq from skin-derived fibroblasts. For 20 individuals, WGS is also available.

The dataset consists of WGS, RNA-seq and proteomics data from 245 individuals diagnosed with ALS and 45 control samples. RNA-seq data were obtained from iPSC-derived spinal motor neurons. We downloaded the data from the Answer ALS portal ( Genes known to be involved in ALS disease development were manually curated from literature28,29,30,31,32.

Variants had to be supported by at least ten reads and had to pass the conservative genotype-quality filter of GQ ≥ 99. These criteria were used for single nucleotide variants (SNVs) and indels in the same way. We considered a variant to be rare if it had an MAF in the general population ≤0.001 based on gnomAD (v.3.1.2) and was found in at most two individuals within each cohort.

Splicing outliers were called using FRASER10 (v.1.6.0) as implemented in the Detection of RNA-seq Outliers Pipeline53 (v.1.1.2). FRASER was used to detect introns (including de novo introns) and to count split reads for each intron. Based on the split-read counts, three intron-centric metrics were calculated: alternative acceptor usage with the ψ5 metric, alternative donor usage with the ψ3 metric, and splicing efficiencies as defined with the θ5 and θ3 metrics54:

where k is the number of split reads supporting the intron from donor D to acceptor A. The sum in the denominator of ψ5(D,A) goes over all possible acceptors A′ for donor D, and the sum in the denominator of ψ3(D,A) goes over all possible donors D′ for acceptor A. In the splicing efficiencies, the denominator contains n(D) or n(A) which are the numbers of nonsplit reads spanning the exon–intron boundary of donor D or acceptor A, respectively. The advantage of these intron-centric metrics over the exon-centric metric percent spliced-in (ψ) is that they do not require exons to be mapped, which is an ill-defined task when starting from short-read RNA-seq data.

FRASER models these metrics while controlling for latent confounders and reports both splice-site-level and gene-level FDRs. We called aberrant spliced genes using the gene-level FDR < 0.1 as in Mertes et al.10 Furthermore, we requested the gene to contain at least one significant splice site (FDR < 0.05, FRASER default) supported by 20 reads and with an absolute deviation of ψ5,3 from the FRASER-modeled expected value larger than 0.3 (denoted |Δψ5,3| > 0.3). The same filters were applied to the splicing efficiency metrics.

To discard aberrant splicing calls that probably have no genetic basis10, we additionally applied and compared different filtering methods (Extended Data Fig. 4). In the GTEx dataset, where multiple RNA-seq samples from the same individual are available, we investigated including splicing outliers from at least two tissues from the same individual (Filter 2; Extended Data Fig. 4b). Here, a gene-level outlier was considered to be replicated if the same splice-site-level outlier was detected in multiple tissues. As this strategy cannot be applied to other single-tissue datasets, we alternatively filtered for splicing outliers containing a rare variant in the vicinity of ±250 bp of every splice site based on RNA-seq from the sample (Filter 3; Extended Data Fig. 4c). Importantly, this filter was applied to all splice sites identified by FRASER, which includes both annotated splice sites as well as cryptic splice sites (Extended Data Fig. 3). For consistency, all reported results are based on Filter 3.

The task is to predict whether a protein coding gene with one or more rare variants within the gene body is aberrantly spliced in a given tissue of an individual.

Due to the large class imbalance in the splicing outlier prediction benchmarking dataset, we chose to evaluate models using precision–recall curves. As evaluation metric we used the auPRC, computed using the average precision (AP) score55 (which represents the mean of precisions for each threshold weighted by the recall difference):

where Pn and Rn are the precision and recall at the nth threshold.

For each tissue separately, we created a SpliceMap that lists all active introns along with aggregate statistics about acceptor and donor site usage useful for aberrant splicing prediction purposes.

We started from all introns reported by FRASER. We filtered out untranscribed splice sites and background noise by filtering out introns not supported by any split-read in more than 95% of the samples. For this and other operations involving genomic ranges we used PyRanges56 (v.0.0.115).

Aggregate statistics were calculated on donor and acceptor sites independently. For donor site usage, the SpliceMap aggregate statistics are (1) the total number of split reads across samples (s) supporting the intron (Σsk), (2) the total number of split reads across samples sharing the same acceptor site (ΣsN3), (3) the median number of split reads per sample sharing the same acceptor site and (4) the reference isoform proportion (\(\psi _3^{\mathrm{ref}}\)), defined as \(\psi _3^{\mathrm{ref}} = \frac{{\mathop {\sum}\nolimits_s k }}{{\mathop {\sum}\nolimits_s {N_3} }}\). Aggregate statistics were computed analogously for acceptor site usage.

To prevent information leakage, the aggregate statistics were computed so that they do not contain information about splicing events associated with rare variants (specifically, we excluded from the computations of the aggregate statistics data from samples with a rare variant within ±250 bp of any donor or acceptor site).

SpliceMaps were also created from split-read (introns) counts using Regtools22 (v.0.5.2) and STAR21 (v.2.5.3) for the ‘Skin – Not Sun Exposed (Suprapubic)’ tissue. We ran Regtools using BAM files. Regtools performs annotation-free counting; thus, it also calls unannotated introns and splice sites. We downloaded STAR split-read counts from the GTEx portal. The GTEx pipeline filters unannotated splice sites, although the STAR two-pass approach could call unannotated splice sites and introns. During SpliceMap generation, active introns and aggregate statistics were computed as described above.

SpliceAI2 (v.1.3.1) is a deep learning model that predicts splice site alteration for acceptor and donor sites from sequence. SpliceAI is annotation free and can therefore score all variants including cryptic splice sites created by deep intronic variants. SpliceAI provides precomputed scores for all SNVs and indels up to the length of 4 nucleotides. These variant scores were computed with 50 bp as the maximum distance between the variant and gained/lost splice sites. We downloaded precomputed variant scores from Illumina BaseSpace and stored them in a RocksDB57 (v.6.10.2) key-value database for fast lookup. We ran SpliceAI to obtain variant scores for long indels not available in the database. Also, we used masked scores of SpliceAI as recommended by the authors for variant interpretation. This masking sets Delta scores to zero if SpliceAI predicts activation for annotated splice sites and deactivation for unannotated splice sites.

We used tissue-specific splice site annotations from SpliceMap together with SpliceAI predictions. For each tissue, we retained those variant scores that contained an annotated splice site within a 100-bp window.

As SpliceAI was trained to predict creation or loss of splice sites and not ψ, there is no principled way to apply the splicing scaling law to include reference levels. Therefore, we used reference levels only to filter predictions. Analogously to the masking of scores representing annotated acceptor/donor gain and unannotated acceptor/donor loss performed by the authors of SpliceAI, we used tissue-specific ψref values for filtering. Specifically, variant scores associated with acceptor/donor gain and a splice site with ψref ≥ 0.95 as well as with acceptor/donor loss and a splice site with ψref ≤ 0.05 were filtered out.

MMsplice3 (v.2.3.0) is a deep learning model that predicts the impact of a variant (in a 100-bp window of annotated splice sites) on alternative usage of a nearby donor or acceptor site. MMSplice predicts the effect of a variant in log-odds ratios (denoted Δlogitψ5 or Δlogitψ3). MMSplice requires a splice site annotation. We used the GENCODE (release 38 of hg38) annotation.

We ran MMSplice on tissue-specific splice site annotations from SpliceMap.

MMSplice is a quantitative model predicting percent spliced-in for which the splicing scaling law can be leveraged to integrate reference levels. For conversion of the variant effect into natural scale, reference levels of donor site and acceptor site usages are required. For the sake of shorter notations, we write in the following ψ instead of ψ5 and ψ3. We used MMSplice to predict Δlogit(ψ) values. Δlogit(ψ) values were then combined with the corresponding reference ψ value (ψref) in SpliceMap: first in logit scale to adjust the predicted variant effect by MMSplice to the correct reference level; then in natural scale by using the sigmoid function (Extended Data Fig. 7a):

Variants further away than 100 bp from any SpliceMap splice site were scored 0 (no effect).

MTSplice9 (v.2.3.0) is a tissue-specific version of MMSplice. The model scores each exon–variant pair for 56 tissues. With respect to each annotated exon boundary, the model takes as input a sequence of 100 bp in the exon and 300 bp in the intron. MTSplice predicts the tissue-specific effect of a variant in log-odds ratios (denoted Δlogit(ψ)). MTSplice requires a splice site annotation. We used the GENCODE (release 38 of hg38) annotation.

CADD-Splice7 is an ensemble model that combines CADD scores (contains conservation scores) together with splicing predictions from SpliceAI and MMSplice. We ran CADD-Splice v.1.6. CADD-Splice provides raw and PHRED-scaled scores. We used the PHRED score.

SQUIRLS8 is based on engineered splicing features for donor and acceptor sites that are extracted from a genome annotation. SQUIRLS predicts the probability of a variant to alter the splicing pattern. We downloaded the SQUIRLS database v.2203 and ran SQUIRLS v.2.0.0.

AbSplice-DNA is a generalized additive model, namely the ExplainableBoostingClassifier from the python package interpretml58. Similar performance was achieved using a random forest or logistic regression model from scikit-learn55. The features of AbSplice-DNA were the prediction score from MMSplice + SpliceMap, MMSplice + SpliceMap + ψref, the SpliceAI Delta score and a binary feature from SpliceMap indicating if the splice site is expressed in the target tissue (using a cutoff of 10 reads for the median number of split reads sharing the splice site). The model includes interaction terms, thereby de facto capturing the effect of combining SpliceMap with SpliceAI scores. The model was trained on a variant level using outliers within 250-bp distance of rare variants as ground truth (Extended Data Fig. 4c before aggregation to gene level). The model was trained with fivefold-stratified cross-validation, grouped by individuals to avoid information leakage, and such that the proportions of the negative (variant is associated with no outlier on the gene) and positive (variant is associated with an outlier on the gene) classes were preserved in each fold.

We used different features from RNA-seq of three CATs from GTEx (Whole blood, Cells transformed fibroblasts, and Cells Epstein-Barr virus (EBV)-transformed lymphocytes) to predict aberrant splicing in nonaccessible target tissues.

As one predictive feature we used the −log10 nominal gene-level P values obtained using FRASER. In the benchmark, we ranked all splicing outlier genes (FDR < 0.1 and |Δψ| > 0.3) lower than the remaining genes, and further ranked genes within each of these two groups by increasing P value.

Additionally, we used SpliceMaps from the accessible and the nonaccessible tissues together with ψ measurements from RNA-seq and applied the splicing scaling law to infer Δψ values in the nonaccessible target tissue:

where ΨCAT is the splicing level in the CAT and \(\varPsi _{\mathrm{ref}}^{\mathrm{CAT}}\) is the reference level of splicing obtained from SpliceMap, and the difference of these two values provides the tissue unspecific variant effect, Δlogit(Ψ). Then, adding Δlogit(Ψ) with the reference level of splicing of the target tissue \({\mathrm{logit}}\left( {\varPsi_{\mathrm{ref}}^{{\mathrm{target}}}} \right)\) in logit scale and converting back to natural scale provides Ψtarget in the target tissue. Subtracting the reference level of splicing of the target tissue, \(\varPsi _{\mathrm{ref}}^{{\mathrm{target}}}\), provides the predicted splicing change in the target tissue, ΔΨtarget, using RNA-seq measurements in CAT.

All precision–recall curves involving CATs have been computed on a subset of the data, excluding CATs from the target tissues and only containing individuals that have RNA-seq measurements from multiple tissues (including the CAT).

We trained integrative models using the two predictors from RNA-seq data from CATs described above in addition to DNA-based features used in AbSplice-DNA.

We trained AbSplice-RNA models using a single CAT and all CATs together. For the model using all CATs together we trained AbSplice-RNA in a CAT-agnostic manner such that the model predicts outliers regardless of the CAT source. This might be helpful in a diagnostic setting as it might be that the available CAT differs from the CATs that AbSplice-RNA was trained on.

For genes with multiple variants, we retained the largest score per model.

Variant categories were annotated with the Ensembl Variant Effect Predictor (VEP)51. For each variant, the most severe VEP annotation was considered. For the ‘Exon’ category, the following VEP categories were grouped together: synonymous_variant, missense_variant, stop_lost, stop_gained. For the nonexclusive splicing outlier categories, we defined ‘exon elongation’, ‘exon truncation’, ‘exon skipping’ using FRASER’s branch: ref. 59. We defined the category ‘Any alternative donor or acceptor choice’ as any ψ5 or ψ3 outlier, and the category ‘Any splicing efficiency outlier’ as any θ outlier.

The enrichment of 165 manually curated genes involved in ALS28,29,30,31 was computed as the proportion of high-splicing-impact variants within those genes, divided by all the high-score predictions of the respective models. Depletion was computed as 1/enrichment.

We downloaded the protein intensities matrix from the ALS cohort consisting of 4,442 proteins and 204 samples from the Answer ALS portal. We considered the 178 affected individuals. Proteins with missing values in more than 30% of the samples were filtered out, with 3,329 remaining. We then ran PROTRIDER60, a denoising autoencoder-based method to detect outliers on proteomics data. The encoding dimension was optimized by injecting outliers. No covariates were provided. Z-scores were extracted from the results table.

For all possible rare SNVs (gnomAD MAF < 0.1%) in 19,534 protein coding genes, we computed AbSplice-DNA scores and obtained the SpliceAI precomputed scores from Illumina BaseSpace. The loss-of-function observed/expected upper bound fraction (LOEUF) scores were downloaded from For each LOEUF decile we computed the proportion of high-splicing-impact variants to the total sum of high-impact variants and divided it by the proportion of rare variants in each decile.

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

No primary data were generated for this study. Rare variants from gnomAD v.3.1.2 are publicly available at The GTEx v8 dataset is available at (under dbGaP protection) The ALS dataset is available at after a registration and approval process. The mitochondrial dataset is described by Yépez et al.27. Precomputed SpliceAI scores are publicly available at Illumina Basespace,, after registration. SpliceMaps for all 49 GTEx tissues and iPSC-derived spinal motor neurons from ALS (hg38) are available at Zenodo, Precomputed AbSplice-DNA scores (hg38) in all 49 GTEx tissues are available at Zenodo, Due to potential donor re-identification when revealing rare variants, the benchmark dataset cannot be shared without restrictions. Users with access to the GTEx data can reproduce the benchmark using the code repository below.

SpliceMaps can be generated using the custom-written python package ‘splicemap’ (publicly available at: ref. 61). AbSplice predictions using the enhanced SpliceMap annotation can be performed with the custom-written python package ‘absplice’ (publicly available at: ref. 62). We also provide a fast implementation of computing SpliceAI predictions using a wrapper based on fast lookup from a database of precomputed scores for existing variants and running SpliceAI for not precomputed variants at ref. 63. Fast lookup of all gnomAD variants can be performed with ref. 64. The analyses are available under ref. 65.

Zappala, Z. & Montgomery, S. B. Non-coding loss-of-function variation in human genomes. Hum. Hered. 81, 78–87 (2016).

CAS PubMed Google Scholar

Jaganathan, K. et al. Predicting splicing from primary sequence with deep learning. Cell 176, 535–548.e24 (2019).

CAS PubMed Google Scholar

Cheng, J. et al. MMSplice: modular modeling improves the predictions of genetic variant effects on splicing. Genome Biol. 20, 48 (2019).

PubMed PubMed Central Google Scholar

Yeo, G. & Burge, C. B. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J. Comput. Biol. 11, 377–394 (2004).

CAS PubMed Google Scholar

Rosenberg, A. B., Patwardhan, R. P., Shendure, J. & Seelig, G. Learning the sequence determinants of alternative splicing from millions of random sequences. Cell 163, 698–711 (2015).

CAS PubMed Google Scholar

Xiong, H. Y. et al. The human splicing code reveals new insights into the genetic determinants of disease. Science 347, 1254806 (2015).

PubMed Google Scholar

Rentzsch, P., Schubach, M., Shendure, J. & Kircher, M. CADD-Splice—improving genome-wide variant effect prediction using deep learning-derived splice scores. Genome Med. 13, 31 (2021).

CAS PubMed PubMed Central Google Scholar

Danis, D. et al. Interpretable prioritization of splice variants in diagnostic next-generation sequencing. Am. J. Hum. Genet. 108, 2205 (2021).

CAS PubMed PubMed Central Google Scholar

Cheng, J., Çelik, M. H., Kundaje, A. & Gagneur, J. MTSplice predicts effects of genetic variants on tissue-specific splicing. Genome Biol. 22, 94 (2021).

CAS PubMed PubMed Central Google Scholar

Mertes, C. et al. Detection of aberrant splicing events in RNA-seq data using FRASER. Nat. Commun. 12, 529 (2021).

CAS PubMed PubMed Central Google Scholar

Jenkinson, G. et al. LeafCutterMD: an algorithm for outlier splicing detection in rare diseases. Bioinformatics 36, 4609–4615 (2020).

CAS PubMed PubMed Central Google Scholar

Ferraro, N. M. et al. Transcriptomic signatures across human tissues identify functional rare genetic variation. Science 369, eaaz5900 (2020).

PubMed PubMed Central Google Scholar

Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434–443 (2020).

CAS PubMed PubMed Central Google Scholar

Wilks, C. et al. recount3: summaries and queries for large-scale RNA-seq expression and splicing. Genome Biol. 22, 323 (2021).

CAS PubMed PubMed Central Google Scholar

Ling, J. P. et al. ASCOT identifies key regulators of neuronal subtype-specific splicing. Nat. Commun. 11, 137 (2020).

CAS PubMed PubMed Central Google Scholar

Kremer, L. S. et al. Genetic diagnosis of Mendelian disorders via RNA sequencing. Nat. Commun. 8, 15824 (2017).

CAS PubMed PubMed Central Google Scholar

Dawes, R., Joshi, H. & Cooper, S. T. Empirical prediction of variant-activated cryptic splice donors using population-based RNA-Seq data. Nat. Commun. 13, 1655 (2022).

CAS PubMed PubMed Central Google Scholar

Frankish, A. et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 47, D766–D773 (2019).

CAS PubMed Google Scholar

Elliott, D. J. & Grellscheid, S. N. Alternative RNA splicing regulation in the testis. Reprodroduction 132, 811–819 (2006).

CAS Google Scholar

de la Grange, P., Gratadou, L., Delord, M., Dutertre, M. & Auboeuf, D. Splicing factor and exon profiling across human tissues. Nucleic Acids Res. 38, 2825–2838 (2010).

PubMed PubMed Central Google Scholar

Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).

CAS PubMed Google Scholar

Cotto, K. C., Feng, Y. Y., Ramu, A. et al. Integrated analysis of genomic and transcriptomic data for the discovery of splice-associated variants in cancer. Nat Commun 14, 1589 (2023).

Glinos, D. A. et al. Transcriptome variation in human tissues revealed by long-read sequencing. Nature 608, 353–359 (2022).

CAS PubMed Google Scholar

Amarasinghe, S. L. et al. Opportunities and challenges in long-read sequencing data analysis. Genome Biol. 21, 30 (2020).

PubMed PubMed Central Google Scholar

Baeza-Centurion, P., Miñana, B., Schmiedel, J. M., Valcárcel, J. & Lehner, B. Combinatorial genetics reveals a scaling law for the effects of mutations on splicing. Cell 176, 549–563.e23 (2019).

CAS PubMed Google Scholar

Cheng, J., Çelik, M. H., Nguyen, T. Y. D., Avsec, Ž. & Gagneur, J. CAGI 5 splicing challenge: improved exon skipping and intron retention predictions with MMSplice. Hum. Mutat. 40, 1243–1251 (2019).

CAS PubMed PubMed Central Google Scholar

Yépez, V. A. et al. Clinical implementation of RNA sequencing for Mendelian disease diagnostics. Genome Med. 14, 38 (2022).

PubMed PubMed Central Google Scholar

Abel, O., Powell, J. F., Andersen, P. M. & Al-Chalabi, A. ALSoD: a user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum. Mutat. 33, 1345–1351 (2012).

CAS PubMed Google Scholar

Gregory, J. M., Fagegaltier, D., Phatnani, H. & Harms, M. B. Genetics of amyotrophic lateral sclerosis. Curr. Genet. Med. Rep. 8, 121–131 (2020).

Google Scholar

Pecoraro, V. et al. The NGS technology for the identification of genes associated with the ALS. A systematic review. Eur. J. Clin. Invest. 50, e13228 (2020).

PubMed PubMed Central Google Scholar

Hardiman, O. et al. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Primers 3, 17071 (2017).

PubMed Google Scholar

McCann, E. P. et al. Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis. J. Med. Genet. (2020).

Cummings, B. B. et al. Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. Sci. Transl. Med. 9, eaal5209 (2017).

PubMed PubMed Central Google Scholar

Frésard, L. et al. Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts. Nat. Med. 25, 911–919 (2019).

PubMed PubMed Central Google Scholar

Aicher, J. K., Jewell, P., Vaquero-Garcia, J., Barash, Y. & Bhoj, E. J. Mapping RNA splicing variations in clinically accessible and nonaccessible tissues to facilitate Mendelian disease diagnosis using RNA-seq. Genet. Med. 22, 1181–1190 (2020).

PubMed PubMed Central Google Scholar

Yates, A. D. et al. Ensembl 2020. Nucleic Acids Res. 48, D682–D688 (2020).

CAS PubMed Google Scholar

Pertea, M., Lin, X. & Salzberg, S. L. GeneSplicer: a new computational method for splice site prediction. Nucleic Acids Res. 29, 1185–1190 (2001).

CAS PubMed PubMed Central Google Scholar

Desmet, F.-O. et al. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 37, e67 (2009).

PubMed PubMed Central Google Scholar

Ke, S. et al. Quantitative evaluation of all hexamers as exonic splicing elements. Genome Res. 21, 1360–1374 (2011).

CAS PubMed PubMed Central Google Scholar

Jian, X., Boerwinkle, E. & Liu, X. In silico prediction of splice-altering single nucleotide variants in the human genome. Nucleic Acids Res. 42, 13534–13544 (2014).

CAS PubMed PubMed Central Google Scholar

Xiong, H. Y. et al. RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease. Science 347, 1254806 (2015).

PubMed Google Scholar

Sonnenburg, S., Schweikert, G., Philips, P., Behr, J. & Rätsch, G. Accurate splice site prediction using support vector machines. BMC Bioinf. 8, S7 (2007).

Google Scholar

Barash, Y. et al. Deciphering the splicing code. Nature 465, 53–59 (2010).

CAS PubMed Google Scholar

Xiong, H. Y., Barash, Y. & Frey, B. J. Bayesian prediction of tissue-regulated splicing using RNA sequence and cellular context. Bioinformatics 27, 2554–2562 (2011).

CAS PubMed Google Scholar

Wainberg, M. et al. Opportunities and challenges for transcriptome-wide association studies. Nat. Genet. 51, 592–599 (2019).

CAS PubMed PubMed Central Google Scholar

Gonorazky, H. D. et al. Expanding the boundaries of RNA sequencing as a diagnostic tool for rare Mendelian disease. Am. J. Hum. Genet. 104, 466–483 (2019).

CAS PubMed PubMed Central Google Scholar

Martorella M. Noninvasive, low-cost RNA-sequencing enhances discovery potential of transcriptome studies. Preprint at bioRxiv (2022).

Teran, N. A. et al. Nonsense-mediated decay is highly stable across individuals and tissues. Am. J. Hum. Genet. 108, 1401–1408 (2021).

CAS PubMed PubMed Central Google Scholar

Rogalska, M. E., Vivori, C. & Valcárcel, J. Regulation of pre-mRNA splicing: roles in physiology and disease, and therapeutic prospects. Nat. Rev. Genet. (2022).

Article PubMed Google Scholar

Zhang, Y., Zhou, R. & Wang, Y. a flexible toolkit for combinatorial analysis of genomic data. Preprint at bioRxiv (2022).

McLaren, W. et al. The ensembl variant effect predictor. Genome Biol. 17, 122 (2016).

PubMed PubMed Central Google Scholar

Tang, A. D. et al. Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia reveals downregulation of retained introns. Nat. Commun. 11, 1438 (2020).

CAS PubMed PubMed Central Google Scholar

Yépez, V. A. et al. Detection of aberrant gene expression events in RNA sequencing data. Nat. Protoc. 16, 1276–1296 (2021).

PubMed Google Scholar

Pervouchine, D. D., Knowles, D. G. & Guigo, R. Intron-centric estimation of alternative splicing from RNA-seq data. Bioinformatics 29, 273–274 (2013).

CAS PubMed Google Scholar

Pedregosa, F. et al. Scikit-learn: machine learning in Python. J. Mach. Learn. Res. 12, 2825–2830 (2011).

Google Scholar

Stovner, E. B. & Sætrom, P. PyRanges: efficient comparison of genomic intervals in Python. Bioinformatics 36, 918–919 (2020).

CAS PubMed Google Scholar

Dong, S., Kryczka, A., Jin, Y. & Stumm, M. RocksDB: evolution of development priorities in a key-value store serving large-scale applications. ACM Trans. Storage 17, 26:1–26:32 (2021).

Google Scholar

Nori, H., Jenkins, S., Koch, P. & Caruana, R. InterpretML: a unified framework for machine learning interpretability. Preprint at arXiv190909223 Cs Stat (2019).

Mertes, C., Scheller, I. & Gagneur, J. FRASER code used in AbSplice publication. Zenodo (2022).

Kopajtich, R. et al. Integration of proteomics with genomics and transcriptomics increases the diagnostic rate of Mendelian disorders. Preprint at (2021).

Wagner, N. et al. SpliceMap code used in AbSplice publication. Zenodo (2022).

Wagner, N. et al. AbSplice code used in AbSplice publication. Zenodo (2022).

Wagner, N. et al. Code to generate SpliceAI rocksdb used in AbSplice publication. Zenodo (2022).

Wagner, N. et al. Code to generate gnomAD rocksdb used in AbSplice publication. Zenodo (2022).

Wagner, N. et al. Analysis code used in AbSplice publication. Zenodo (2022).

Download references

We thank I. Scheller for feedback and advice. M.H.C. thanks X. Xie and A. Mortazavi for institutional support. The German Bundesministerium für Bildung und Forschung (BMBF) supported the study through the Model Exchange for Regulatory Genomics project (MERGE; grant no. 031L0174A to F.R.H. and J.G.), the German Network for Mitochondrial Disorders (mitoNET; grant no. 01GM1906B to V.A.Y.), the ERA PerMed project PerMiM (grant no. 01KU2016A to H.P. and grant no. 01KU2016B to J.G.) and the EJP RD project GENOMIT (grant no. 01GM1920A to H.P.). N.W. is supported by the Helmholtz Association under the joint research school ‘Munich School for Data Science – MUDS’. This study was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), via the projects ‘Identification of host genetic variation predisposing to severe COVID-19 by genetics, transcriptomics and functional analyses’ (grant no. 466168909 to V.A.Y. and J.G.) and NFDI 1/1 ‘GHGA - German Human Genome-Phenome Archive’ (grant no. 441914366 to C.M. and J.G.). Figure 1 was created with The Genotype-Tissue Expression (GTEx) project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by the NCI, NHGRI, NHLBI, NIDA, NIMH and NINDS. This study was supported by data provided by the Answer ALS Consortium, administered by the Robert Packard Center for ALS at Johns Hopkins. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

These authors contributed equally: Nils Wagner, Muhammed H. Çelik.

School of Computation, Information and Technology, Technical University of Munich, Garching, Germany

Nils Wagner, Muhammed H. Çelik, Florian R. Hölzlwimmer, Christian Mertes, Vicente A. Yépez & Julien Gagneur

Helmholtz Association – Munich School for Data Science (MUDS), Munich, Germany

Nils Wagner & Julien Gagneur

Center for Complex Biological Systems, University of California, Irvine, Irvine, CA, USA

Muhammed H. Çelik

Munich Data Science Institute, Technical University of Munich, Garching, Germany

Christian Mertes

Institute of Human Genetics, School of Medicine, Technical University of Munich, Munich, Germany

Holger Prokisch & Julien Gagneur

Computational Health Center, Helmholtz Center Munich, Neuherberg, Germany

Holger Prokisch & Julien Gagneur

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

You can also search for this author in PubMed Google Scholar

J.G. conceptualized the project. N.W., M.H.C. and J.G. designed the methodology. N.W. and M.H.C. provided the software. N.W., M.H.C., F.R.H., H.P. and V.A.Y. performed validations. N.W., M.H.C., F.R.H., V.A.Y. and C.M. performed the formal analysis. N.W., M.H.C., F.R.H. and V.A.Y. curated the data. N.W., M.H.C., V.A.Y. and J.G. wrote the original draft of the manuscript. All authors reviewed and edited the manuscript. N.W., M.H.C., F.R.H., V.A.Y. and J.G. performed visualizations. J.G. supervised the project.

Correspondence to Julien Gagneur.

The authors declare no competing interests.

Nature Genetics thanks Jamie Ellingford, Xin Gao and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

a, Distribution of the area under the precision-recall curve across GTEx tissues (n = 49) of different prediction methods (SpliceAI, SpliceAI using SpliceMap annotation, SpliceAI using SpliceMap annotation along with quantitative reference levels of splicing, MMSplice using GENCODE annotation, MMSplice using SpliceMap annotation, MMSplice using SpliceMap annotation along with quantitative reference levels of splicing, and the integrative model AbSplice-DNA) taking as ground truth 3 different aberrant splicing callers: FRASER, LeafcutterMD and SPOT. A gene was considered aberrantly spliced if it contained at least one significant splicing outlier reported by the aberrant splicing caller without applying any additional replication or rare variant filter (Extended Data Fig. 4a for FRASER). Center line, median; box limits, first and third quartiles; whiskers span all data within 1.5 interquartile ranges of the lower and upper quartiles. P values were computed using the paired one-sided Wilcoxon test. b, Precision-recall curves comparing the overall prediction performance on all GTEx tissues of the same models as in a, using FRASER as the outlier caller and the rare variant filter in Extended Data Fig. 4c with 250 bp together with different differential splicing cutoffs, namely |ΔΨ| = 0.1, 0.2, 0.3.

a, Enrichment of replicated splicing outliers across tissues with respect to the distance to the nearest rare variant. Note that there is an enrichment up to a distance of 250 bp. ‘Number of tissues’ denotes the minimum number of tissues from an individual with a shared splicing outlier such that the outlier is considered to be replicated. b, Replication rate of aberrant splicing events between tissues (n = 49) of a sample for all aberrant splicing events (red) compared with aberrant splicing events that contain a rare variant within a 250 bp window (blue). Filtering for aberrant splicing events with a rare variant reduces the amount of singletons probably by filtering out technical artifacts. Center line, median; box limits, first and third quartiles; whiskers span all data within 1.5 interquartile ranges of the lower and upper quartiles. c, Percentage of singletons (aberrant splicing events that are observed only in one tissue) among all outliers (in red) and among outliers with a rare variant (in blue) for each tissue. There are nearly no replicated RNA-seq samples in the GTEx dataset. Therefore, among all singleton events, genuinely tissue-specific aberrant splicing events are hard to distinguish from non-reproducible technical artifacts.

Visualization of different cases for the rare variant outlier filter (corresponds to Filter 3 in Extended Data Fig. 4). a, Exons 1, 3 and 4 were annotated in SpliceMap. Exon 2 is a novel exon detected on an individual whose splice sites are not in SpliceMap. If there exists a rare variant within 250 bp of any splice site (in SpliceMap or not) that shares a junction with either the donor or acceptor site of the outlier event, the outlier passes the ‘rare variant filter’. Cases 1 and 2: The individual has a rare variant within 250 bp of either the donor site of exon 1 or the acceptor site of exon 2, which are the splice sites of the outlier junction. Importantly, exon 2 was not quantified by SpliceMap, but the outlier filter solely depends on split reads. Case 3: The individual has a rare variant within 250 bp of the donor site of exon 2. However, this donor site is not part of the outlier event. Case 4: The individual has a rare variant within 250 bp of the acceptor site of exon 3, which forms a splicing junction with the donor site of exon 1. Case 5: The individual has two rare variants, one further than 250 bp of any splice site, the other within 250 bp of the acceptor site of exon 4. Notably, a variant can be far from the outlier junction and still be involved in the outlier event. b, Exon elongation detected as a splicing efficiency outlier. For splicing efficiency outliers, only the affected splice-site with altered splicing efficiency is considered for the variant filter. Case 1: The individual has a rare variant within 250 bp of the donor site of exon 1. Case 2: The individual has a rare variant that overlaps the acceptor site of the elongated exon 3, but is further than 250 bp from the acceptor site of exon 3. Case 3: The individual has a rare variant within 250 bp of the acceptor site of exon 3. Case 4: The individual has a rare variant within 250 bp of the donor site of exon 3, but the donor is not related to the exon elongation.

Precision-recall curve comparing the overall prediction performance on all GTEx tissues of SpliceAI, SpliceAI using SpliceMap annotation, SpliceAI using SpliceMap annotation along with quantitative reference levels of splicing, MMSplice using GENCODE annotation, MMSplice using SpliceMap annotation, MMSplice using SpliceMap annotation along with quantitative reference levels of splicing, and the integrative model AbSplice-DNA, using different filters for aberrantly spliced genes. a, Filter 1: FRASER default cutoffs (|ΔΨ| > 0.3, FDR < 0.05, 126,308 aberrant events) b, Filter 2: same as a, but restricting to genes that are aberrantly spliced in at least two different tissues from the same individual (32,886 aberrant events). c, Filter 3: same as a, but restricting to genes that have a rare variant within 250 bp of the splice sites (22,766 aberrant events). While the results are best with Filter 3, the relative improvements in terms of precision at the same recall between the methods is the same as with Filter 2. In particular, having restricted to variants 250 bp away from any detected split read boundary (Filter 3) did not bias our analysis for the splice-site centric method MMSplice over SpliceAI. d, After applying Filter 3, outliers were stratified into ‘replicated’ (14,030 aberrant events), that is appearing in at least two different tissues of the same individual, and ‘not replicated’ (8,736 aberrant events). All models showed a significantly higher performance for aberrant splicing events replicated in two or more samples compared to those reported in a single sample only.

a, A gene model with 3 annotated exons in the standard annotation (1, 3 and 4) and 3 exons detected by SpliceMap (1, 2 and 4). SpliceAI scores for every bp in a 50 bp window of a variant (shown as red star) and reports the maximum score independent of the distance to a junction. MMSplice provides a score in a 100 bp window around a variant as long as there is a junction in that window. b, Case with a variant within 100 bp of an annotated junction in SpliceMap, but further than 100 bp from any exon in the standard annotation. MMSplice + SpliceMap is able to score the variant, while MMSplice is not. c, Case with a variant within 100 bp of an annotated exon in the standard annotation, but further than 100 bp from any exon in the SpliceMap. Therefore, MMSplice is able to score the variant, while MMSplice + SpliceMap is not. d, The variant is not within 100 bp of any annotated junction in the standard annotation or SpliceMap. Therefore neither MMSplice nor MMSplice + SpliceMap can score the variant. However, SpliceAI is always able to score a variant. Consequently, AbSplice is always able to score a variant.

Number of introns, acceptor sites, and donor sites annotated in GENCODE and the SpliceMap of each GTEx tissue (first row), GENCODE only (second row) and SpliceMap only (third row).

a, Ψ against Δlogit(Ψ) showing the non-linear splicing scaling law. The mutation effect of a variant can lead to different changes in Ψ in natural scale, depending on the reference splicing level of the intron. For example, the same variant can lead to a large change in Ψ if Ψref is initially at an intermediate level and almost no change if Ψref is initially at an extreme value (here low). b, Distribution of Ψref in SpliceMap. Most of the introns are not alternatively spliced, so the reference level of those introns is either 0 or 1. c, Cumulative distribution function of the maximum difference of Ψref (defined as: max(Ψref) - min(Ψref)) across tissues per intron. d, Heatmap of the Ψref of the most variable introns (defined as: max(Ψref) - min(Ψref) > 0.3) across tissues.

a, Histogram of AbSplice-DNA scores for gene, sample, tissue combinations that do not contain an aberrant splicing event. The dashed red line indicates the median. b, Histogram of AbSplice-DNA scores for gene, sample, tissue combinations that contain an aberrant splicing event. The peak at logit(AbSplice-DNA) ~-3.1 corresponds to AbSplice-DNA scores that are low due to small SpliceAI and MMSplice scores, but with an expressed splice site as annotated in SpliceMap. The peak at logit(AbSplice-DNA) ~-4.3 corresponds to small SpliceAI and MMSplice scores with an unused splice site as annotated in SpliceMap. c, Odds of aberrant splicing events as a function of logit transformed AbSplice-DNA scores (binned in bins of width 0.1). The line represents the diagonal. Note the linear relationship (especially in the high AbSplice-DNA score region) and the (extrapolated) intersection at AbSplice-DNA score of 0.5 (logit(AbSplice-DNA) = 0) corresponding to a log odds of 1, indicating a well calibrated model.

a, Precision-recall performance of CADD-Splice, SQUIRLS, MTSplice, MMSplice and SpliceAI. b, Distribution of the area under the precision-recall curve (auPRC) across all GTEx tissues (n = 49) of the AbSplice-DNA models trained with varying feature sets using the models in a, that is ‘AbSplice-DNA (+ CADD-Splice)’ additionally used CADD-Splice scores during training. Center line, median; box limits, first and third quartiles; whiskers span all data within 1.5 interquartile ranges of the lower and upper quartiles. Shown in red is the AbSplice-DNA model used in the manuscript. Models are sorted by auPRC. P-values were computed using the paired two-sided Wilcoxon test. c-d, AbSplice-DNA was trained using a generalized additive model (GAM), random forest and logistic regression. AbSplice-DNA with GAM is the one used in the manuscript. c, Precision-recall curve across all GTEx tissues. d, Distribution of the area under the precision-recall curve of the models in c across tissues (n = 49). Center line, median; box limits, first and third quartiles; whiskers span all data within 1.5 interquartile ranges of the lower and upper quartiles.

a, Precision-recall curves comparing the overall prediction performance on non-accessible GTEx tissues using the gene-level FRASER p-values from the CAT, AbSplice-RNA trained on a single CAT and AbSplice-DNA. Each panel shows a different CAT and the number of matching samples in the non-accessible tissues. b, Same as a, but for samples having RNA-seq from both blood and fibroblasts. AbSplice-RNA (all CATs) was trained using RNA-seq data from blood, fibroblasts and lymphocytes. Note that AbSplice-RNA (fibroblasts) gave a similar performance as AbSplice-RNA (all CATs). We did not restrict the samples to the ones also having lymphocytes as this would result in a low number of samples (N = 2,258). c, Model performance for genes not expressed or expressed in the clinically accessible tissue fibroblasts. The cutoff for calling a gene expressed was TPM > 1 (transcript per million). AbSplice-RNA improves for genes expressed in fibroblasts and remains on par with AbSplice-DNA for genes not expressed in fibroblasts.

Supplementary Figs. 1–7 and Table 1.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

Wagner, N., Çelik, M.H., Hölzlwimmer, F.R. et al. Aberrant splicing prediction across human tissues. Nat Genet 55, 861–870 (2023).

Download citation

Received: 05 April 2022

Accepted: 14 March 2023

Published: 04 May 2023

Issue Date: May 2023


Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Nature Genetics (2023)